This proposed rule focuses primarily on PMTA overview methods and information specifications, significantly with respect to software acceptance and filing. An software may perhaps meet up with the acceptance and filing specifications, but still deficiency critical information and facts that FDA needs to ascertain no matter whether it need to challe